JAX starts canine cancer initiative to find predictors, treatments for humans, dog

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Jackson Laboratory launched the Tallwood Canine Cancer Research Initiative, which will create a biobank of dog tumors that the nonprofit biomedical research institution plans to use and share with researchers around the world to provide new insights into cures for cancer in humans and dogs.

JAX will identify and work closely with veterinary centers. When a canine patient at one of the JAX’s veterinary partner organizations is diagnosed with a cancer of interest, its owner can opt to have the veterinarian donate their dog’s tumor to TCCRI when it’s removed during the dog’s cancer treatment.

JAX will use the tumor to create a patient-derived xenograft cancer model and sequence each tumor model established, much like the organization’s human PDX resource. PDX tumors are grown in mice, and can provide information including how cancer changes over time and what therapeutics are most effective. JAX will use these PDX models for its ongoing cancer research programs, as well as make them available to researchers around the world to accelerate the process of cancer treatment discovery.

JAX investigators will also sequence the DNA from healthy canines of specific breeds.

JAX received a $500,000 gift for the Tallwood Canine Cancer Research Initiative from an anonymous Hartford-area donor. The TCCRI project began last month with the collection of DNA from the first healthy canine sample—the donor family’s dog, Patrick, an Irish Wolfhound.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login